Canada markets closed

Seres Therapeutics Inc (1S9.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
0.7318+0.0204 (+2.87%)
At close: 09:53PM CEST
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
126,847
126,325
7,128
144,927
33,215
-
Operating Expenses
Research Development
123,593
145,860
172,920
141,891
90,570
-
Selling General and Administrative
80,740
87,744
79,694
69,261
30,775
-
Total Operating Expenses
203,848
234,308
253,618
209,420
121,345
-
Operating Income or Loss
-77,001
-107,983
-246,490
-64,493
-88,130
-
Interest Expense
15,891
13,176
6,020
2,910
2,924
-
Total Other Income/Expenses Net
2,292
134
-705
-1,045
981
-
Income Before Tax
-82,683
-113,724
-250,157
-65,578
-89,127
-
Income from Continuing Operations
-82,683
-113,724
-250,157
-65,578
-89,127
-
Net Income
-82,683
-113,724
-250,157
-65,578
-89,127
-
Net Income available to common shareholders
-82,683
-113,724
-250,157
-65,578
-89,127
-
Basic EPS
-1.11
-
-2.31
-0.72
-1.12
-1.24
Diluted EPS
-1.11
-
-2.31
-0.72
-1.12
-1.24
Basic Average Shares
126,765
-
108,077
91,703
79,789
56,649
Diluted Average Shares
126,765
-
108,077
91,703
79,789
56,649